Last updated: August 7, 2026
Novartis Pharmaceuticals Corp. v. Accord Healthcare Inc., No. 1:18-cv-01043, was an ANDA patent case involving generic fingolimod hydrochloride, the active ingredient in Novartis’ Gilenya multiple-sclerosis product. The principal patent was U.S. Patent No. 9,187,405, which claimed a method of treating multiple sclerosis with a 0.5 mg daily fingolimod dose.
The case formed part of broader Gilenya generic litigation. The key result was unfavorable to Novartis: the asserted dosing patent was found invalid for obviousness, removing the principal patent barrier to generic fingolimod approval and launch. The litigation also illustrates the limits of method-of-use patents when the claimed dose is supported by clinical data but the underlying dose-selection process is viewed as routine optimization.
What drug and patent were involved in Novartis v. Accord?
The case involved Gilenya, an oral disease-modifying therapy for relapsing forms of multiple sclerosis.
| Item |
Detail |
| Brand product |
Gilenya |
| Active ingredient |
Fingolimod hydrochloride |
| Applicant and patent holder |
Novartis Pharmaceuticals Corp. |
| Generic defendant |
Accord Healthcare Inc. |
| FDA pathway |
Abbreviated New Drug Application, or ANDA |
| Court |
U.S. District Court for the District of Delaware |
| Case number |
1:18-cv-01043 |
| Principal patent |
U.S. Patent No. 9,187,405 |
| Patent subject matter |
Fingolimod dosing method for multiple sclerosis |
| Asserted dose |
0.5 mg once daily |
| Primary legal issue |
Whether the claimed dosing regimen was obvious |
The ’405 patent covered treatment of multiple sclerosis using a lower fingolimod dose than the higher dose evaluated in earlier clinical work. Novartis relied on the patent to delay approval of Accord’s proposed generic product.
What patents protected Gilenya against generic entry?
The ’405 patent was the central patent asserted against Accord in this litigation. Its claims were directed to a treatment regimen rather than to a new chemical compound.
U.S. Patent No. 9,187,405
The patent covered the use of fingolimod, or a related compound, at a specified low daily dose for treating multiple sclerosis. The commercial relevance of the patent came from its association with Gilenya’s approved 0.5 mg dose.
The patent had a statutory expiration date in 2027, subject to any applicable patent-term adjustment or extension. The patent’s expiration date was materially later than the expiration of Novartis’ basic compound and composition protections, making it a principal later-life exclusivity asset for Gilenya.
The patent did not broadly protect every fingolimod product. Its value depended on whether a generic applicant’s labeling, proposed use, or prescribing information induced infringement of the claimed multiple-sclerosis dosing method.
Earlier Gilenya patents
Novartis’ Gilenya estate also included earlier patents covering fingolimod compounds, pharmaceutical compositions, and related uses. Those earlier rights were less significant by the time of the Accord case because their expiration dates were earlier than the ’405 patent.
The commercial dispute therefore centered on the method-of-use patent, not on a continuing composition-of-matter monopoly.
When did Novartis sue Accord, and what triggered the litigation?
Novartis filed the case after receiving a Paragraph IV certification from Accord’s ANDA filing.
Under the Hatch-Waxman Act, a Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. A patent owner’s suit within 45 days generally triggers a 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii).
The litigation involved the standard ANDA disputes:
- Whether Accord’s proposed fingolimod product would infringe the ’405 patent.
- Whether the patent claims were invalid for obviousness.
- Whether the claims satisfied the written-description and enablement requirements.
- Whether Novartis could enforce the patent against a generic product whose labeling directed use for multiple sclerosis.
The litigation was part of a broader group of cases involving other generic applicants challenging the same Gilenya patent.
What were the main infringement issues?
Novartis argued that Accord’s proposed generic product would be used according to the patented 0.5 mg regimen. The infringement theory focused on induced infringement and the relationship between the ANDA labeling and the claimed method of treatment.
Label-based infringement
For method-of-use claims, an ANDA applicant may face infringement exposure if its proposed labeling encourages physicians to perform the patented method. The inquiry generally examines the wording of the label, dosage instructions, approved indications, and the practical use of the generic product.
Novartis’ position was that a generic fingolimod label aligned with Gilenya’s approved multiple-sclerosis indication and 0.5 mg dose would encourage the claimed treatment.
Accord challenged the infringement theory and argued that the ANDA product and proposed labeling did not establish infringement of the asserted claims. The court’s analysis, however, ultimately focused on patent validity rather than creating a durable infringement precedent for generic fingolimod.
Why was the Gilenya ’405 patent held invalid?
The principal invalidity issue was obviousness under 35 U.S.C. § 103.
The court evaluated whether a person of ordinary skill in the art would have been motivated to select the claimed 0.5 mg dose, whether the prior art supplied a reasonable expectation of success, and whether the clinical results represented an unexpected result sufficient to overcome an obviousness showing.
Novartis’ validity position
Novartis relied on the clinical advantages associated with the lower dose, including a favorable balance between efficacy and safety. The company argued that the prior art did not make the claimed dosing regimen predictable and that the lower dose produced unexpected clinical benefits.
Generic defendants’ position
The generic defendants argued that:
- Fingolimod was already known as an effective multiple-sclerosis therapy.
- Dose selection was a routine optimization exercise.
- The prior art disclosed a range of possible doses.
- Skilled researchers would have tested lower doses to reduce adverse effects.
- The clinical results did not establish a sufficient unexpected-benefit profile over the prior art.
The court accepted the generic defendants’ obviousness position. The Federal Circuit later affirmed the invalidity determination in the related appellate proceedings involving the ’405 patent.
What was the litigation outcome?
The outcome eliminated the ’405 patent as a reliable barrier to generic fingolimod approval.
| Issue |
Outcome |
| Patent asserted |
U.S. Patent No. 9,187,405 |
| Infringement dispute |
Litigated in the ANDA action |
| Validity challenge |
Generic defendants prevailed |
| Obviousness |
Patent claims held invalid |
| Federal Circuit posture |
Invalidity judgment affirmed in related appeal |
| Commercial effect |
Reduced protection for Gilenya’s 0.5 mg dosing regimen |
| Generic entry effect |
Removed the principal later-expiring method-of-use obstacle |
The invalidity ruling did not invalidate every Novartis patent associated with fingolimod. It addressed the asserted patent claims in the litigation. The commercial consequence was still substantial because the ’405 patent was one of the principal remaining rights supporting Gilenya’s late-life exclusivity.
What was the FDA and Orange Book status of Gilenya?
Gilenya was approved by the FDA in 2010 for relapsing forms of multiple sclerosis. It was the first oral disease-modifying therapy approved for that market segment.
The Orange Book listed Gilenya patents submitted by Novartis in connection with the approved product. The ’405 patent was listed as a method-of-use patent. Its listing allowed Novartis to invoke Hatch-Waxman litigation after a Paragraph IV certification by a generic applicant.
FDA approval and commercial launch remained separate questions. A court ruling on patent validity removed the patent-based approval obstacle, but launch timing could still depend on:
- FDA review of the ANDA;
- product-specific deficiencies;
- pediatric exclusivity;
- other listed patents;
- settlement agreements;
- manufacturing readiness; and
- regulatory injunctions or stays.
Did the case involve a Paragraph IV settlement?
The public record for the 1:18-cv-01043 litigation should be distinguished from any separate settlement agreements involving other Gilenya generic applicants. ANDA litigation often includes defendant-specific settlements, authorized-generic arrangements, or launch dates that do not apply uniformly across all challengers.
The invalidity result against the ’405 patent reduced the value of any settlement designed solely to preserve that patent. After invalidation, Novartis’ leverage would have shifted toward other patents, regulatory exclusivities, supply arrangements, or commercial terms.
No settlement should be assumed to create a uniform generic launch date for all Accord-related or Gilenya-related defendants.
Which companies challenged Gilenya’s patent estate?
Novartis faced multiple generic challenges to Gilenya patents. Publicly reported litigation involved several major generic manufacturers, including Accord and HEC, among other applicants.
The competitive landscape included:
| Company type |
Strategic objective |
| Accord Healthcare |
Obtain FDA approval for generic fingolimod |
| Other ANDA applicants |
Challenge the ’405 patent and related Gilenya rights |
| Novartis |
Preserve late-life Gilenya sales and delay generic substitution |
| FDA |
Review ANDAs independently of the patent merits |
| Pharmacies and payers |
Shift utilization after generic approval and launch |
The invalidity ruling had class-wide strategic significance because the ’405 patent was a common barrier for multiple generic applicants. A final judgment against the patent weakened Novartis’ position across the broader litigation group.
How strong was Novartis’ Gilenya patent estate?
The estate was strongest during the period covered by compound and composition patents. Its later-stage strength depended more heavily on method-of-use claims.
| Estate component |
Relative strength in the Accord litigation |
| Fingolimod compound protection |
Stronger historically, but earlier expiration |
| Pharmaceutical composition claims |
Product-specific and time-limited |
| Multiple-sclerosis treatment claims |
Commercially important but vulnerable to obviousness attacks |
| 0.5 mg dosing regimen |
Central asserted protection, ultimately invalidated |
| Manufacturing rights |
Potentially relevant, but not the principal issue in this case |
| Regulatory exclusivity |
Separate from patent validity and expiration |
The case shows the risk of relying on clinical-dose patents as the principal post-compound exclusivity layer. A lower dose can produce important safety benefits, but those benefits do not automatically establish nonobviousness. The patent must connect the claimed dose to a technical advance that the prior art did not make reasonably predictable.
What generic launch risks remained after the ruling?
After invalidation of the ’405 patent, generic entry risk increased materially. The remaining obstacles were primarily regulatory and commercial rather than centered on that patent.
Regulatory risk
FDA approval could still be delayed by:
- unresolved chemistry, manufacturing, and controls issues;
- facility inspections;
- labeling deficiencies;
- bioequivalence questions; or
- product-specific administrative review.
Patent risk
Novartis could continue to rely on any unexpired, uninvalidated patents that were properly listed and relevant to the proposed generic product. Those patents would require separate infringement litigation and separate validity analysis.
Commercial risk
Generic entrants faced normal launch risks, including:
- payer formulary positioning;
- substitution rules;
- wholesale discounts;
- inventory buildup;
- competition among multiple approved applicants; and
- potential authorized-generic competition.
The ruling did not guarantee that Accord would be the first or only generic entrant. It removed a major patent obstacle but did not determine each applicant’s regulatory approval date or commercial strategy.
What was the revenue exposure for Novartis?
Gilenya was a major Novartis product before generic competition. The product generated multibillion-dollar annual sales at its peak, making the ’405 litigation material to Novartis’ multiple-sclerosis franchise.
The revenue risk arose from three mechanisms:
- Generic substitution could reduce unit volume.
- Price erosion could compress net sales even if prescription demand remained stable.
- Earlier generic entry could accelerate the decline of the product’s established commercial base.
The patent ruling also affected the value of Novartis’ remaining Gilenya rights in licensing, settlement, and portfolio transactions. Once the principal dosing patent was invalidated, prospective counterparties would place greater weight on regulatory status, remaining patents, manufacturing capabilities, and market access.
What does the case mean for pharmaceutical patent strategy?
The case has four practical implications.
Dose-selection patents require a strong technical record
Clinical success alone is insufficient. The patentee must show why the selected dose was not an obvious optimization and why the observed benefits were unexpected relative to the prior art.
Method-of-use claims depend heavily on labeling
A generic applicant’s proposed label can create infringement exposure even when the product itself is chemically identical to the branded product. The claim construction and induced-infringement analysis must focus on actual label instructions and use.
Orange Book listing does not establish validity
Listing the ’405 patent created the statutory mechanism for litigation and the 30-month stay. It did not protect the patent from an invalidity judgment.
Patent-term layering has limits
A later-expiring dosing patent can extend nominal protection beyond composition patents. Its commercial value remains dependent on surviving obviousness, written-description, enablement, and infringement challenges.
Key Takeaways
- Novartis Pharmaceuticals v. Accord Healthcare, 1:18-cv-01043, involved generic fingolimod for Gilenya.
- U.S. Patent No. 9,187,405, covering a 0.5 mg daily multiple-sclerosis treatment regimen, was the principal patent at issue.
- The generic defendants prevailed on obviousness.
- The invalidity ruling materially reduced Novartis’ ability to delay generic Gilenya entry.
- The case was a method-of-use patent dispute, not a challenge to every fingolimod patent.
- FDA approval, other patents, settlements, and commercial launch timing remained separate issues.
- The ruling weakened the value of Novartis’ late-life Gilenya patent estate and increased generic-entry risk.
FAQs About Novartis v. Accord Healthcare and Gilenya
What is the case number for the Novartis Gilenya litigation against Accord?
The case number is No. 1:18-cv-01043 in the U.S. District Court for the District of Delaware.
Which active ingredient was covered by Accord’s proposed generic?
Accord’s proposed product contained fingolimod hydrochloride, the active ingredient in Gilenya.
Did the litigation concern Entresto?
No. The Accord case identified by docket number 1:18-cv-01043 concerned Gilenya and fingolimod dosing claims, including U.S. Patent No. 9,187,405.
Does invalidation of the ’405 patent invalidate all Gilenya patents?
No. The judgment addressed the asserted claims in the litigation. Other Gilenya patents required separate validity, infringement, and expiration analyses.
Can a generic launch immediately after a patent-invalidity ruling?
Not necessarily. FDA approval, other listed patents, regulatory exclusivity, injunctions, settlements, and manufacturing readiness can affect launch timing.
References
-
Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. U.S. Department of Health and Human Services.
-
Novartis Pharmaceuticals Corp. v. Accord Healthcare Inc., No. 1:18-cv-01043, U.S. District Court for the District of Delaware.
-
Novartis Pharmaceuticals Corp. v. HEC Pharm. Co., related Federal Circuit appeal concerning U.S. Patent No. 9,187,405.
-
U.S. Patent and Trademark Office. (2015). U.S. Patent No. 9,187,405: Methods of treating multiple sclerosis. U.S. Department of Commerce.
-
U.S. Food and Drug Administration. (2010). FDA approves first oral drug to reduce multiple sclerosis relapses. U.S. Department of Health and Human Services.
